Familial hemophagocytic lymphohistiocytosis hepatitis is mediated by IFN-γ in a predominantly hepatic-intrinsic manner

Tamir Diamond, Thomas N. Burn, Mailyn A. Nishiguchi, Danielle Minichino, Julie Chase, Niansheng Chu, Portia A. Kreiger, Edward M. Behrens

1 Division of Gastroenterology Hepatology and Nutrition, Children’s Hospital of Philadelphia, Philadelphia, PA, United States of America, 2 Perlman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States of America, 3 Division of Rheumatology, Children’s Hospital of Philadelphia, Philadelphia, PA, United States of America, 4 Department of Pathology, Children’s Hospital of Philadelphia, Philadelphia, PA, United States of America

* diamondt@chop.edu

Abstract

Interferon gamma (IFN-γ) is the main cytokine driving organ dysfunction in Familial Hemophagocytic Lymphohistiocytosis (FHL). Blockade of IFN-γ pathway ameliorates FHL hepatitis, both in animal models and in humans with FHL. Hepatocytes are known to express IFN-γ receptor (IFN-γ-R). However, whether IFN-γ induced hepatitis in FHL is a lymphocyte or liver intrinsic response to the cytokine has yet to be elucidated. Using a IFNgR−/− bone marrow chimeric model, this study showed that non-hematopoietic IFN-γ response is critical for development of FHL hepatitis in LCMV-infected Prf1−/− mice. Lack of hepatic IFN-γ responsiveness results in reduced hepatitis as measured by hepatomegaly, alanine aminotransferase (ALT) levels and abrogated histologic endothelial inflammation. In addition, IFN-γ non-hematopoietic response was critical in activation of lymphocytes by soluble interleukin 2 receptor (sIL-2r) and recruitment of CD8+ effector T lymphocytes (CD8+ CD44hi CD62Llo) (Teff) and inflammatory monocytes. Lastly, non-hematopoietic IFN-γ response results in increased hepatic transcription of type 1 immune response and oxidative stress response pathways, while decreasing transcription of genes involved in extracellular matrix (ECM) production. In summary, these findings demonstrate that there is a hepatic transcriptional response to IFN-γ, likely critical in the pathogenesis of FHL hepatitis and hepatic specific responses could be a therapeutic target in this disorder.

1. Introduction

Cytokine Storm Syndromes (CSS) are a group of disorders of various etiologies that culminate in a common final pathway of systemic inflammation affecting multiple organs and driving high rates of mortality [1]. Acute liver injury resulting in rapid decompensation in function is a common manifestation of many CSS, including familial hemophagocytic lymphohistiocytosis (FHL) and macrophage activation syndrome (MAS). Hyperactivation of effector CD8+ T-cells producing abundant interferon gamma (IFN-γ) are the main immunopathological drivers in these disorders clinically and in experimental models [2–5].
FHL type 2 (FHL2) is caused by mutations in the perforin gene (Prf1), which results in dysfunctional cytolysis by CD8+ T-cells causing persistent antigen exposure. Consequently, CD8+ T-cell proliferation and activation, with excessive production of cytokines such as IFN-γ, results in multisystemic organ dysfunction with high morbidity and mortality [6]. A murine model of FHL2 (Prf1−/−) develops a phenotype similar to human disease and has been extensively used to elucidate cytokine storm syndromes in general and FHL specifically [2]. The work in this model demonstrating depletion of CD8+ T cells and blockade of IFN-γ ameliorating disease provided the pre-clinical basis for development of a novel treatment for blocking this cytokine in human disease (empalumab) [7–10].

The liver is an organ with a unique immunological milieu. Its role as a filter barrier to the outside environment for metabolically essential nutrients as well as pathogens and harmful toxins, necessitate its complex interaction with the immune system [11]. Hepatocytes have an IFN-γ receptor (IFNγR) that induces an antiviral, anti-tumor and tissue regenerative response, including upregulation of anti-viral defense, cell cycle arrest and apoptosis pathways [12–14]. In vitro experiments and in vivo models of CSS describe the role of IFN-γ in hepatic injury [4, 5, 15–17]. Moreover, recent publications from our group showed that in the FHL2 (Prf1−/−) model, canonical signals of tissue injury may contribute to FHL pathophysiology in addition to IFN-γ leukocyte response in the liver [18, 19]. However, despite our knowledge that CD8+ T cell production of IFN-γ plays a significant role in pathogenesis of FHL, there are no studies to date that assess the targets of IFN-γ, either acting directly on liver tissue, or on immune cells, to initiate or promote injury.

In the current study, we sought to determine if IFN-γ-mediated hepatic injury in the murine model of FHL is caused by direct effect of IFN-γ on the liver, or by IFN-γ acting on lymphocytes that in turn mediate injury. We used bone marrow (BM) chimeras to assess how non-hematopoietic response to IFN-γ signaling in FHL model may result in hepatitis by using lethal irradiation of hosts and injection of BM cells from donors that were either IFNγ-R deficient or sufficient. Our observations establish that lack of IFN-γ response in the liver as a non-hematopoietic organ is hepatoprotective independent of leukocyte response to IFN-γ. In addition, we found that non-hematopoietic IFN-γ response is necessary for recruitment of inflammatory monocytes and CD8+ effector T lymphocytes (CD8+ CD44hi CD62Llo) (Teff). Lastly, transcriptomic analysis of hepatic IFN-γ response showed alteration in cellular metabolic oxidative stress response and production of ECM in addition to inflammatory pathways.

2. Materials and methods

2.1. Mice

C57BL/6 (wild-type), perforin-deficient (C57BL/6-Prf1tm1Sdz/J, Prf1−/−), IFN-γ-R–deficient (B6.129S7-Ifngr1tm1Agt/J, IFNγR−/−), mice were purchased from The Jackson Laboratory and bred in our facility. Prf1−/− mice were cross-bred with IFNγR−/− mice to create Prf1−/− IFNγR−/−. Euthanasia was achieved via CO2 chamber and cardiac puncture. Anesthesia performed using 3% Isoflurane with 2% oxygen delivered in anesthesia chamber. All animal studies were performed with approval from The Children’s Hospital of Philadelphia Institutional Animal Care and Use Committee.

2.2. Generation of bone marrow chimeras

BM chimeras were created to assess hepatocyte response to IFN-γ signaling in FHL model. All mice were deficient in Prf1 (Prf1−/−) and either deficient or sufficient in IFNγR expression. Mice 6-11-week-old Perforin-deficient (Prf1−/− IFNγR−/−) and Perforin-IFN-γ-R–deficient (Prf1−/−IFNγR−/−) hosts were lethally irradiated (950 Rad on an X-RAD irradiator). BM was
isolated from donor strains ($Prf1^{-/-} \text{IFNgR}^{+/+}$ or $Prf1^{-/-} \text{IFNgR}^{-/-}$) and $3.5 \times 10^6$ BM cells were injected intravenously to host 6 hours after irradiation. We generated all pairwise combinations of genotype in marrow or host resulting in $Prf1^{-/-}$ mice that were selectively deficient in IFN-$\gamma$-R in the bone marrow, non-hematopoietic tissues, both of these compartments, or neither compartment. All chimeras were normal in appearance and behavior prior to any infections.

2.3. Induction of FHL and acute hepatitis

8–14 weeks after creation of BM chimeras to allow for marrow reconstitution, chimeric mice were infected intraperitoneally with $2 \times 10^5$ plaque-forming units of Lymphocytic Choriomeningitis Virus (LCMV) (Armstrong strain). Mice were sacrificed 8 days after infection when features of FHL become apparent. Mice were euthanized earlier if developed significant morbidity or weight loss (e.g. $>$20%) [18–20].

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured from serum using a Roche Cobas c311 clinical chemistry analyzer. Complete blood count with differential (CBC) was analyzed using Sysmex XT-2000i hematology analyzer. Serum IFN-$\gamma$ and soluble interleukin-2 receptor (sIL-2r) were measured by enzyme-linked immunosorbent assay (ELISA) using BD Biosciences and R&D Systems commercial kits respectively according to protocol.

2.4. Histologic analysis

Unperfused livers were fixed for 24 hours in 4% paraformaldehyde and either stained with hematoxylin and eosin (H&E) or embedded in paraffin. Slides were read with grading of lobular inflammatory score, necrosis, steatosis, portal inflammation and endothelial injury score by pediatric pathologist blinded to treatment protocols (PAK). The established grading criteria of endothelial injury were previously published [21]. Images were acquired on an Eclipse 90i microscope (Nikon, Melville, NY) using NIE-ELEMENTS software.

2.5. Flow-cytometric analysis

Intrahepatic leukocytes were isolated using a Percoll (GE Healthcare Life Sciences) density gradient centrifugation. 2/3 of each liver was disrupted using a 70-micron filter. The cell pellet was resuspended in 30% Percoll, layered over 70% Percoll, and centrifuged. The interface formed contained the intrahepatic leukocytes and stained with LIVE/DEAD fixable viability dye (Life Technologies) and CD4, CD8α, NK1.1, B220, Ly6C, Ly6G, CD11b, CD44, CD62L, CXCR3 and CD90.2 (BD, Pharmingen, eBioscience and BioLegend). Splenocytes were stained with LIVE/DEAD fixable viability dye and B220, CD44, CD4, CD90.2, CD62L, CD8α (S1 Table). All samples were acquired on a MACSQuant flow cytometer (Miltenyi Biotec) and analyzed using FlowJo software version 10.6 (Tree Star). (See S1 and S2 Figs for gating strategy.)

2.6. Messenger RNA sequencing (mRNA-seq) data analysis and visualization

Fresh mouse liver segments were stored in RNAlater® solution (Thermo Fisher Scientific) at -20°C and thawed for RNA extraction at later date. RNA extraction was performed in livers of 4 mice from the BM $\text{IFNgR}^{+/+}$ and host $\text{IFNgR}^{-/-}$ group and 4 mice from the BM $\text{IFNgR}^{+/+}$ and host $\text{IFNgR}^{+/+}$ group using the Qiagen RNeasy Mini Kit protocol from approximately 30mg of homogenized tissue according to manufacturer instructions. Prepared RNA samples
and libraries were assessed for quality and quantified using an Agilent Tapestation 4200 and Qubit 3, respectively. Libraries were prepared using the Illumina TrueSeq stranded mRNA library prep (Illumina). Samples were sequenced on an Illumina NextSeq 500 to produce 65 bp single-end reads with a mean sequencing depth of 4 million reads per sample.

Raw reads were mapped to the mouse reference transcriptome (Ensembl, Mus musculus version 101) using Kallisto version 0.46.0 [22]. All subsequent analyses were carried out using the statistical computing environment, R (version 4.0.0) in RStudio (version 1.1.453) and Bioconductor (version 3.11). The TxImport package was used to summarize transcript quantification data to genes [23]. Data was normalized using the TMM method in EdgeR and filtered for genes with < 1 count per million (CPM) in 4 samples (the number of replicates per genotype) [24]. Processed data were variance-stabilized using the VOOM function in limma [25]. After correcting for multiple testing using Benjamini-Hochberg, linear modeling using limma (FDR \( \leq 0.05 \); absolute logFC \( \geq 1 \)), was performed to identify differentially expressed genes. Gene ontology (GO) analysis was performed using Database for Annotation, Visualization and integrated Discovery (DAVID) (https://david.ncifcrf.gov/) Raw sequence data is available on the Gene Expression Omnibus (GEO, accession #GSE168086).

2.7. Quantitative real-time polymerase chain reaction

RNA was isolated from snap frozen livers in OCT using TRIzol LS (Thermo Fisher Scientific) with RNAeasy Mini Kit (Qiagen). Isolated RNA was converted to complementary DNA using the Superscript III First-Strand Synthesis System (Life Technologies) and subjected to quantitative real-time polymerase chain reaction using QuantiTect primers for Cxcl9, Igtpl, Irgm1 and Stat1 (Qiagen) and Power SYBR Green master mix (Life Technologies). Results were normalized to \( \beta \)-actin (Actb) using \( \Delta \Delta CT \) method.

2.8. Quantitative Glutathione S-Transferase activity

Fresh mouse liver tissue was extracted, sectioned and weighed so all samples were 50 mg. Tissue was rinsed in phosphate buffered saline (PBS) to remove blood. Tissue was the homogenizer in 250 \( \mu \)L of cold 100 mM potassium phosphate, pH 7 with 2 mM EDTA. All samples were subsequently frozen in -80°C to lyse cells. After freezing and thaw cycle, specimens were centrifuged at 10,000xg for 15 minutes at 4°C. Supernatant from samples was removed and assayed using Invitrogen™ Glutathione S-Transferase (GST) Fluorescent Activity Kit (Thermo Fischer Scientific) according to instructions.

2.9. Statistical analysis

All data were analyzed in GraphPad Prism 8 using statistical tests indicated in the figure legends and results section. Unless otherwise specified, P-values are represented by number or symbols (e.g. * \( P<0.05 \), ** \( P<0.01 \), *** \( P<0.001 \)).

2.10. Data sharing

The raw data supporting the conclusion in this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

3. Results

3.1. Bone marrow IFN-\( \gamma \) signaling results in pronounced features of FHL

Consistent with our previous published results, all groups developed certain characteristics of FHL independent of IFN-\( \gamma \)-R response in either the host or BM, including weight loss (Fig 1A),
splenomegaly (Fig 1B), elevated serum IFN-γ, sIL-2r (Fig 1C and 1D), lower end of normal range of leukocytes (WBC), red blood cells (RBC) and thrombocytopenia (Fig 1E–1G) [19, 26]. There was no significant difference in day 8 mortality between groups with all having less than 9% mortality. Serum IFN-γ levels were highest in completely receptor deficient (IFNgR−/− BM in host IFNgR−/−) group, compared to the BM deficient only (IFNgR−/− BM in host IFNgR+/+) and host deficient only (IFNg+/+ BM in host IFNgR−/−) groups, with an intermediate level in completely sufficient (IFNgR+/+ BM in host IFNgR+/+) mice (Fig 1C). This supports previous data showing serum IFN-γ levels are not only modified by Teff production via a positive IFN-γ feedback loop, but also consumption by IFN-γ-R, in both leucocytes and non-immune tissue [19]. In addition, sIL-2r serum levels were significantly elevated in all groups compared to uninfected WT (mean 439.8pg/mL range 159.24–645.0, data not shown) and previously reported LCMV infected WT [19]. sIL-2r levels were dependent on both BM and host IFN-γ-R response in a synergistic interaction (Fig 1D). This suggests that IFN-γ effect on non-immune organs contributes to lymphocyte activation in addition to a lymphocyte intrinsic response. Notably, splenomegaly was entirely driven by BM IFN-γ-R response (Fig 1B), while host IFN-γ-R signaling reduced the degree of weight loss (Fig 1A). The degree of thrombocytopenia was driven mainly by BM IFN-γ-R responsiveness. However, when there was non-hematopoietic signaling of IFN-γ (IFNgR+/+ BM in IFNgR−/− host), thrombocytopenia was milder compared to whole body IFNgR−/− group (Fig 1G).

3.2. Non-hematopoietic IFN-γ response produces murine FHL hepatitis and endothelial injury in a cell intrinsic manner

We investigated the contribution of IFN-γ-R signaling in the hepatic and BM derived leukocyte response in hepatitis using a 2-way ANOVA model. To determine variance in hepatic IFN-γ-R response was from BM derived leukocytes or liver intrinsic signaling we performed quantitative PCR for liver extracted mRNA of 4 canonical downstream genes- chemokine ligand 9 (Cxcl9), interferon gamma induced GTPase (Igtp1), immunity-related GTPase family M member 1 (Irgm1) and signal transducer and activator of transcription 1 (Stat1). BM IFN-γ-R response did not contribute significantly to hepatic transcription to any of the 4 interferon-γ-inducible genes (S1 Fig). This suggested there was a transcriptional hepatic interferon-γ response that was independent of BM response. As expected, there was a significant contribution of BM IFN-γ-R response to hepatocyte injury. However, the non-hematopoietic IFN-γ-R response worsened liver injury, independent of BM driven injury as measured by hepatomegaly and ALT (Fig 2A and 2B). Interestingly, AST, a less specific marker for hepatocellular injury, did not show a significant difference in non-hematopoietic IFN-γ-R mediated response (Fig 2C). Histologically, livers analyzed from hosts that were IFNgR−/− (Fig 2E) had a significantly lower percent of endothelial inflammatory activity compared to IFNgR+/− livers (Fig 2F). This host effect was independent of BM IFN-γ-R response when analyzed by multiple logistic regression analysis (Fig 2D–2F).
3.3. Non-hematopoietic IFN-γ response contributes to CD8+ T effector cell (CD8+ CD44$^{hi}$ CD62L$^{lo}$) and inflammatory monocyte predominance in hepatic inflammation

After observing the non-hematopoietic cell contribution of IFN-γ-R response to liver injury, we evaluated the hepatic inflammatory milieu as compared to peripheral blood and spleen (S2 & S3 Figs for gating strategy). There was no significant difference in either BM or host IFN-γ-R response in peripheral blood monocytes, lymphocytes and neutrophils, although the host IFNgR−/− groups showed a trend of neutrophilia. (S4A–S4C Fig). Splenic B-cell and naïve CD8+ T-cells (CD8+ CD44$^{lo}$ CD62L$^{hi}$) cells were significantly higher when lymphocytes were unresponsive to IFN-γ and the non-hematopoietic IFN-γ response was intact (S4D and S4E Fig). This interaction was not observed in the splenic Teff cell population (S4F Fig). This suggests mobilization from lymphoid tissue of B-cells and naïve CD8 T-cells to periphery is controlled by a complex interplay of lymphocyte intrinsic and non-immune organ response to IFN-γ.

Histologic assessment of hepatic inflammation revealed a lobular inflammatory score demonstrating inflammatory recruitment is mainly driven by BM IFN-γ-R response with a trend showing non-hematopoietic contribution that was not statistically significant (Fig 3A). However, a more quantitative analysis using flow cytometry of intrahepatic leukocytes showed an independent contribution of hepatic IFN-γ-R response to leukocyte recruitment (Fig 3B). Non-hematopoietic IFN-γ-R signaling was critical for hepatic lymphocyte recruitment of both B Cells (Fig 3C) and T-cells for which BM and hepatic IFN-γ-R signaling contributed independently (Fig 3D). When evaluating the different T-cell sub-populations, recruitment of hepatic...
IFN-γ mediated hepatitis in familial hemophagocytic lymphohistiocytosis
CD8+ T-cells, particularly Teff (CD8+ CD44hi CD62Llo) cells, were dependent on non-hematopoietic IFN-γ-R response, independently of the BM response (Fig 3E–3G). Liver myeloid infiltration was also under the control of non-hematopoietic IFN-γ-R. Inflammatory monocytes (Ly6C+, Ly6G-, CD11b+) were significantly elevated in livers that were IFN-γ-R responsive (Fig 4A). We previously described the regulation of neutrophil survival in FHL being mediated by IFN-γ in a neutrophil-intrinsic manner. The IFN-γ-R neutrophil response results in increased apoptosis rather than decrease in BM production [19]. In this current study, we observed an increase in hepatic neutrophil recruitment when liver IFN-γ-R signaling was absent, but this was not statistically significant (Fig 4B). These findings suggest that IFN-γ regulates inflammatory monocyte tissue infiltration predominantly by the non-hematopoietic response to the cytokine directly but that neutrophil responses are largely cell-intrinsic.

3.4. Non-hematopoietic IFN-γ response increases hepatic cellular stress pathways and decreases extracellular matrix production in FHL

To determine the downstream effects of non-hematopoietic intrinsic IFN-γ response on the transcriptional level, we performed messenger RNA sequencing (mRNAseq) from IFN-γ-R deficient (IFNgR−/−) and sufficient (IFNgR+/+) livers, both reconstituted with IFN-γ-R-sufficient bone marrow (IFNgR+/+ BM) in our chimeric FHL model. As we described above, the number of intrahepatic leukocytes was modestly affected by hepatic IFN-γ-R response (Fig 3B). However, leukocytes still make up a minority of the cells in these livers, meaning that the bulk of the mRNA extracted will be of liver origin and therefore unlikely to contribute to transcriptional

![Figure 4](https://doi.org/10.1371/journal.pone.0269553.g004)
differences between groups. Consistent with the notion that hepatic leukocyte variance between groups was minimal, there was no significant difference in PTPRC (which encodes the leukocyte marker CD45) transcription between groups (data not shown but accessible at GEO #GSE168086). Additionally, as described above in section 3.2 BM IFN-γ-R response did not contribute significantly to hepatic transcription of downstream interferon-inducible genes of the IFN-γ pathway (S1 Fig).

Comparing IFNgR+/+ to IFNgR−/− livers, there was a higher number of transcripts of Stat1 and Cxcl9 in the IFNgR+/+ livers (Fig 5A), which was confirmed using quantitative real-time polymerase chain reaction (S1 Fig). This is correlated with a non-hematopoietic IFN-γ-R dependent decrease in chemokine receptor 3 (CXCR3)+ surface expression in liver CD8+ Teff and CD4+ T cells, an event well described in response to CXCL9 (S5–S7 Figs) [27]. Furthermore, infiltration of CXCR3+ inflammatory monocytes is decreased in IFNgR−/− livers, particularly when IFN-γ-R is absent in the bone marrow, suggesting a non-hematopoietic intrinsic role for IFN-γ induced CXCL9 in monocyte recruitment (S5C and S5D Fig). In addition, transcripts of Mixed lineage kinase domain like pseudokinase gene (MLKL), which is a known mediator of hepatocyte death induced by IFN-γ, were increased in IFNgR−/− livers, indicative of direct IFN-γ mediated hepatocyte injury (Fig 5A and S2 Table) [28, 29]. This result confirmed a differential IFN-γ response in livers that were receptor sufficient (IFNgR+/+) compared to deficient (IFNgR−/−). Unsurprisingly, analysis of differentially expressed genes via GO analysis using the DAVID toolset, found a transcriptional enrichment in both innate and type 1 adaptive immune response in IFNgR+/+ livers compared to IFNgR−/− (Table 1, Fig 5B and S2 Table).

Interestingly, there was an enrichment in pathways associated with gene transcription of cytochrome P-450 (CYP450) drug metabolism by GST activity as well as oxidoreductases in IFNgR+/+ livers compared to IFNgR−/−. These genes included those involved in glutathione metabolism as well as certain CYP450 isoforms (Cyp26a1, Cyp2a12, Cyp2g1, Cyp3a41b) (Table 1 and Fig 5C and 5D and S2 Table). We evaluated if transcriptional enrichment correlates to hepatic GST enzymatic activity using fluorescent activity assay. GST activity was entirely dependent on hepatic IFN-γ-R response, which correlated with decrease enzymatic activity in livers sufficient for the receptor (S8 Fig) This is consistent with a hepatic response to IFN-γ that results in decreased GST activity and a compensatory transcriptional increase in GST mRNA. In addition to these differences, the main pathways that were transcriptionally enriched in the IFNgR−/− livers compared to IFNgR+/+ were those involved in collagen synthesis and extra cellular matrix (ECM) production (Table 2, Fig 5E and 5F and S3 Table). These results indicate that IFN-γ mediated ECM remodeling disruption is an intrinsic transcriptional element of hepatic pathology in FHL and correlates to the parenchymal collapse described histologically in FHL hepatitis in humans [30].

4. Discussion
This study reveals that non-hematopoietic IFN-γ response has a hepatic effect to produce liver injury in FHL pathophysiology. Liver resident Kupffer cells and dendritic cells may be resistant to irradiation and may also alter the immune response and affect the inflammatory physiology of FHL [31, 32]. Thus, some of the host effect could be attributed to these cell types. Future work in cell lineage specific receptor deleted mice will clarify these issues. The IFN-γ response in the liver alters immune and metabolic pathways correlating with liver injury and is also critical in recruitment of the main immune-mediators of disease, Teff and inflammatory monocytes. This provides novel insight to the mechanism of IFN-γ response in immune pathogenesis of FHL hepatitis.
Non-hematopoietic IFN-γ response increases cellular stress response and reduces ECM production in the liver. Mice with IFNγR+/+ BM and either IFNγR+/+ or IFNγR−/− livers (n = 4 per group) were sacrificed 8 days after LCMV infection to induce FHL hepatitis and livers were harvested for mRNAseq analysis. (A) Volcano plot comparing genes that transcripts were decreased (shaded in blue) and increased (shaded in red) in IFNγR−/− livers when compared to IFNγR+/+ livers as reference. X axis notes the log fold change (logFC) using IFNγR+/+ livers as reference and Y axis notes the log adjusted p value [-log10(adj.p.val)]. Heatmaps showing relative expression from the individual genes from the pathways (B-D) upregulated and (E-F) downregulated by the presence of IFNγR according to GO analysis using DAVID. Genes are
One of the basic limitations of our model is its inability to differentiate between specific cell populations of liver parenchyma such as hepatocytes, stellate cells, tissue resident immune cells, liver sinusoidal endothelial cells (LSEC) or other non-hematopoietic tissue contributing to FHL pathology. However, significantly increased transcripts of Stat1, Igtp1, Irgm1 and Cxcl9, all downstream interferon-inducible genes, in IFNgR+/+ livers without a significant contribution of BM IFN-γ-R response, indicate a hepatic intrinsic response is induced during disease. While we cannot completely rule out non-hepatic, non-immune factors and radioresistant hepatic dendritic and Kupffer cells contributing to the liver specific effects of FHL, taken together these data suggest that non-hematopoietic responses to IFN-γ are contributing to liver pathology. Further, elucidation of the various hepatic compartments’ contribution to IFN-γ induced hepatitis in FHL using Cre mediated, lineage specific deletion will be a goal of future work.

We observed significantly higher levels of serum IFN-γ, neutrophilia and weight loss in the mice who lacked IFN-γ-R in both BM and non-immune cells consistent with our description of mice natively deficient in the receptor demonstrating the fidelity of our chimeric system [19]. Platelet count was primarily driven by BM response to IFN-γ but there was a synergistic contribution in ameliorating thrombocytopenia when the non-immune organs could sense IFN-γ via the IFN-γ-R. sIL-2r is a marker for T-cell activation which is elevated in CSS hepatitis from various etiologies [30, 33–35]. Interestingly, we observed that sIL-2r levels were dependent not only on leukocyte response to IFN-γ but also on non-immune organ response in the host synergistically, suggesting a non-immune organ response to IFN-γ may contribute T-cell hyper-activation in FHL. This might be attributed to the liver sinusoidal environment, which regulates both T-cell activation via antigen presentation and recruitment by CXCR3 ligands facilitated by LSEC [36]. However, this could also be due to sIL-2r production by non-immune tissues themselves as was observed clinically by Bode et al. where HLH developed in patients with severe combined immunodeficiency manifesting in an absence of T cells, yet still had elevated sIL-2r [37]. We conclude that while certain IFN-γ induced immunopathology characteristics in FHL are entirely hematopoietic-intrinsic (spleen size), the sensing of IFN-γ by non-immune organs determines certain phenotypic features of FHL such as lymphocyte activation and thrombocytopenia.

Hepatocytes are known to express IFN-γ-R, which assists in innate and type 1 immune response to hepatotropic viruses and other environmental insults to which mammals are exposed [12, 38]. The hepatic response is involved in cell death, recruitment of leukocytes, inhibition of fibrosis and metabolic changes [12, 28, 29, 38]. Prenice et al. described a hepatic upregulation in transcription of genes involved in the IFN-γ pathway in children suffering

| Gene Set Origin | Pathway Function | Number of genes in cluster (% of total) | Benjamini score (adj. p value) |
|-----------------|------------------|----------------------------------------|-------------------------------|
| INTERPRO        | Interferon-inducible GTPase | 11 (7.3) | 2.9E-15 |
| GOTERM_BP_DIRECT| Cellular Response to interferon-beta | 13 (8.6) | 4.1E-14 |
| GOTERM_MF_DIRECT| GTP binding | 22 (14.6) | 2E-10 |
| KEGG_PATHWAY    | Drug metabolism—cytochrome P450 | 10 (6.6) | 2.6E-7 |
| UP_KEYWORDS     | Oxidoreductase | 15 (9.9) | 4.6E-3 |
| INTERPRO        | Glutathione S-transferase, C-terminal | 7 (4.6) | 3.2E-6 |
| INTERPRO        | MHC class I-like antigen recognition | 9 (6) | 4.5E-7 |
| KEGG_PATHWAY    | Antigen processing and presentation | 10 (6.6) | 1.1E-6 |

https://doi.org/10.1371/journal.pone.0269553.t001
from secondary hemophagocytic lymphohistiocytosis (HLH) with hepatitis, supporting the
hypothesis that hepatocyte IFN-γ response could contribute to liver injury in HLH [3]. Using
our compartmentalization of immune and non-immune responses in the mouse model of
FHL2, we were able to demonstrate that the non-hematopoietic IFN-γ response contributes to
liver injury in an independent manner from the leukocyte response. The elevation of ALT,
hepatomegaly and histological findings of endothelial injury, which were all driven by the
non-immune IFN-γ-R phenotype, indicate its response is critical to pathogenesis in FHL hepa-
titis and are observed in children suffering from FHL [39, 40].

We found that there are IFN-γ-R effects on transcription that were non-hematopoietic
mediated resulting in altered hepatic metabolic response as part of immunopathology. These
included GST and the oxidoreductases in the CYP450 metabolic pathways, specifically in the
cyp2 iso-enzymes. Transcription is modified in various inflammatory environments such as
infection, cancer and autoimmune disorders. The main determinants of CYP450 expression
are cytokines, particularly IFN-γ, interleukin (IL)-1, IL-6 and tumor necrosis factor α (TNF-α)
which modify expression of various isoforms of CYP450 family depending on the inflamma-
tory milieu [41]. Schuck et al. showed in a murine model of nonalcoholic fatty liver disease
(NAFLD) that part of the inflammatory pathogenesis in NAFLD is mediated by suppression
of activity of various isoforms of the CYP2 family [42]. Similarly, we show that hepatic GST enzy-
matic activity is suppressed by non-hematopoietic IFN-γ response yet increases in transcription
may be compensatory to reduce oxidative stress as part of cytolytic effect of the cytokine.
Reduction of oxidative stress is known to enhance type 1 and 2 IFN response against hepatitis
C in both animal models and humans [43, 44]. Our findings showing IFN-γ response results
in increased transcription of genes involved in the GST pathway but decrease in enzymatic
activity, suggests that part of the IFN-γ hepatic response is compensatory to reduce cellular
oxidative stress in hepatocytes as has been described in infectious hepatitis [44].

The anti-fibrotic effects of IFN-γ in viral hepatitis have been extensively described in
humans and animal models [45–49]. Weng et al. showed a significant decrease in hepatic
fibrosis scores of patients with hepatitis B treated with IFN-γ compared to placebo [48]. The
same group showed that IFN-γ works as an antagonist to tumor growth factor-β effects in
hepatic stellate cells (HSC) resulting in reduction of ECM production [49]. Work in animal
models of toxin and infectious fibrosis describe the effects of IFN-γ in reduction of ECM pro-
duction by direct effect on metabolic pathways in HSC or reduction of number of HSC by Nat-
ural Killer cells [38, 46, 47]. In our model the main pathways enriched in IFN-γ-deficient
hepatic response as compared to sufficient livers were related to ECM production. This sug-
gests that the protective role IFN-γ has against infectious or toxic or infectious causes of liver
injury, may alternatively result in liver dysfunction when produced in a dysregulated manner
such as in FHL.

The effects of hepatic response to IFN-γ in recruitment of leukocytes is of great importance
as we learn more about T-cell mediated hepatic injury in CSS. Prencipe et al. showed recently
that there is hepatic upregulation in Cxcl9 gene transcripts in a murine model of MAS, as part
of the IFN-γ response, similarly to what the group described in human livers [3, 5]. In our

Table 2. Gene pathways enriched in IFNγ-R-/- livers.

| Gene Set Origin | Pathway Function                                      | Number of genes in cluster (% of total) | Benjamini score (adj. p value) |
|-----------------|-------------------------------------------------------|----------------------------------------|-------------------------------|
| UP_KEYWORDS     | Disulfide bond                                        | 46 (57.5)                              | 1.8E-17                       |
| GOTERM_CC_DIRECT| Proteinaceous extracellular matrix                     | 16 (20)                                | 5.9E-11                       |
| INTERPRO        | Collagen triple helix repeat                          | 8 (10)                                 | 2.7E-6                        |
| UP_KEYWORDS     | Secreted mediators                                    | 36 (45)                                | 1.8E-17                       |

https://doi.org/10.1371/journal.pone.0269553.t002
current study, we were able to establish this transcriptional response is dependent on the non-immune hepatic IFN-γ-R. By compartmentalization of the IFN-γ response, we describe the pathophysiological effect of this cytokine on hepatic recruitment of cellular mediators of disease and its effect on the inflammatory milieu. The increase in hepatic recruitment of CD8+ T cells and inflammatory monocytes, was driven by non-hematopoietic IFN-γ-R genotype independently from the BM response and correlates to the increase in Cxcl9 gene transcripts in this group. This work provides evidence that tissue injury by direct cytokine toxicity/response may contribute to FHL inflammation in addition to IFN-γ effects on immune cells. In addition, our findings provide evidence of the important role of the liver, as an immunomodulatory organ, in recruitment of cells critical to the immunopathology of CSS and the interplay between these two compartments (Fig 6).

![Fig 6. Mechanistic depiction of liver injury in Familial Hemophagocytic Lymphohistiocytosis (FHL) physiology](https://doi.org/10.1371/journal.pone.0269553.g006)
In summary, our current study demonstrates that non-hematopoietic response to IFN-\(\gamma\) is critical for pathogenesis of FHL hepatitis independent of the immune response. Absence of hepatic IFN-\(\gamma\) response results in amelioration of hepatic dysfunction, endotheliitis, ECM disruption as well as recruitment and activation of immune main mediators of FHL hepatitis and suggest IFN-\(\gamma\) blockade may be viable hepatoprotective strategy in FHL and other CSS.

**Supporting information**

**S1 Fig. Hepatic expression of canonical downstream genes increases in response to IFN-\(\gamma\).** Liver mRNA transcripts of Cxcl9 (A), Stat1 (B), Igt1 (C) and Irgm1 (D) were compared between 4 chimera groups using 2 way ANOVA to assess variability between host and BM IFNgR genotypes. P-values are denoted in box embedded in the graphs, medians are depicted in the horizontal line. Symbols denote individual mice. AU, arbitrary units.

**(TIFF)**

**S2 Fig. Liver gating strategy.** Example of gating strategy for intrahepatic leukocytes. Panel A was used to identify B cell (Live, B220+, CD90.2-), T-cell populations (Live, B220-, CD90.2+, CD4+ or CD8+), neutrophils (Live, B220-, CD90.2-, Ly6G+ Cd11b+) and inflammatory monocytes (Live, B220-, CD90.2-, Ly6G-, CD11b+, Ly6c+) (A). Panel B was used to identify NK cells (Live, NK1.1+,CD90.2-), NKT cells (Live, NK1.1, CD90.2) and CD8 subpopulations: naïve T cells (Live, NK1.1-, CD90.2+, CD8+, CD44+, CD62L+), T-effector cells (Live, NK1.1-, CD90.2+, CD8+, CD44+, CD62L-) and T-central memory cells (Live, NK1.1-, CD90.2+, CD8+, CD44+, CD62L+).

**(TIFF)**

**S3 Fig. Spleen gating strategy.** Example of gating strategy for splenocytes. Panel used to identify B cell (Live, B220+, CD90.2-), T-cell populations (Live, B220-, CD90.2+, CD4+ or CD8+) and CD8 subpopulations: naïve T cells (Live, NK1.1-, CD90.2+, CD8+, CD44+, CD62L+), T-effector cells (Live, NK1.1-, CD90.2+, CD8+, CD44+, CD62L-) and T-central memory cells (Live, NK1.1-, CD90.2+, CD8+, CD44+, CD62L+).

**(TIFF)**

**S4 Fig. Mobilization of B-cells, Naïve C8+ cells from lymphoid tissue to periphery requires both lymphocyte intrinsic and host response to IFN-\(\gamma\).** Peripheral neutrophils (A), lymphocytes (B) and monocytes (C) counts were compared between 4 chimera groups (n \(\geq\)5 mice per group) using 2 way ANOVA to assess variability between host and BM IFNgR genotypes. Blue represents IFNgR+/+ and red IFNgR/- in BM (zebra filling) and non-hematopoietic (violin plot boarder). Splenic B-cells (D), naïve T cell (CD8+ CD44lo CD62Lhi) (E) and T effector Cell (CD8+ CD44hi CD62Llo) (F) counts were compared between 4 chimera groups (n \(\geq\)15 mice per group) using 2 way ANOVA to assess variability between host and BM IFNgR genotypes. P-values are denoted in box embedded in the graphs, medians and quartiles are depicted in the dashed and dotted lines respectively.

**(TIF)**

**S5 Fig. Non-hematopoietic IFN-\(\gamma\) response results in decrease expression of hepatic CXCR3 on T lymphocytes.** Quantitative assessment of CXCR3+ expression by mean fluorescence intensity (MFI) in T cell population (B220-, CD90.2-) (A) CD8+ Teff (B220-, CD90.2+, CD8+, CD44hi CD62Llo), (B) CD4+ cells (B220-, CD90.2+, CD4+,CD8-), and (C) inflammatory monocytes (iMonos) (B220-, CD90.2-, Ly6G-, CD11b+, Ly6C+) (D) Absolute numbers of CXCR3+ iMonos in liver parenchyma. (E) Representative CXCR3+ histogram showing decreased expression of surface CXCR3 in Teff population in mice with IFNgR+/+ liver.
compared to mice with livers deficient in IFNgR. All data was analyzed using 2-way ANOVA with p values denoted in box embedded in the graphs, medians are depicted in the horizontal line. Symbols denote individual mice.

**S6 Fig. Liver flow gating strategy panel A.** Panel was used to determine CXCR3+ expression. B cells (Live, B220+, CD90.2-) were used as negative control. T-cell populations (Live, B220-, CD90.2+, CD4+ or CD8+), neutrophils (Live, B220-, CD90.2-, Ly6G+Cd11b+) and inflammatory monocytes (Live, B220-, CD90.2-, Ly6G-, CD11b+, Ly6c+) were gated to assess CXCR3+ cells and then MFI to determine expression of receptor.

**S7 Fig. Liver flow gating strategy Panel B.** Panel was used to determine CXCR3+ expression. B cells (Live, B220+, CD90.2-) were used as negative control. CD8 subpopulations: naïve T cells (Live, CD90.2+, CD8+, CD44+, CD62L+), T-effector cells (Live, CD90.2+, CD8+, CD44+, CD62L-) and T-central memory cells (Live, CD90.2+, CD8+, CD44-, CD62L+) were gated to assess CXCR3+ cells and then MFI to determine expression of receptor.

**S8 Fig. Liver Glutathione S-Transferase (GST) activity is decreased by IFNgR signaling.** Quantitative assessment of hepatic GST activity using fluorescent activity assay (Thermo Scientific™) showing decreased activity in livers responsive to IFNgR signaling. All data was analyzed using 2-way ANOVA with p values denoted in box embedded in the graphs, medians are depicted in the horizontal line. Symbols denote individual mice.

**S1 Table. List of antibodies used.**

**S2 Table. Genes with increased expression in IFNγ-R+/+ livers.**

**S3 Table. Genes with decreased expression in IFNγ-R+/+ livers.**

**Acknowledgments**

We would like to thank Dr. Kathleen M. Loomes for her critical review of this manuscript and the Children’s Hospital of Philadelphia Pathology and Translational Cores.

**Author Contributions**

**Conceptualization:** Tamir Diamond, Thomas N. Burn, Edward M. Behrens.

**Data curation:** Tamir Diamond, Thomas N. Burn, Danielle Minichino, Julie Chase, Niansheng Chu, Portia A. Kreiger.

**Formal analysis:** Tamir Diamond, Mailyn A. Nishiguchi, Portia A. Kreiger, Edward M. Behrens.

**Funding acquisition:** Tamir Diamond, Edward M. Behrens.

**Methodology:** Edward M. Behrens.

**Software:** Mailyn A. Nishiguchi.
Supervision: Edward M. Behrens.

Validation: Tamir Diamond.

Writing – original draft: Tamir Diamond, Edward M. Behrens.

Writing – review & editing: Tamir Diamond, Thomas N. Burn, Mailyn A. Nishiguchi, Danielle Minichino, Julie Chase, Niansheng Chu, Portia A. Kreiger, Edward M. Behrens.

References

1. Canna SW, Behrens EM. Making Sense of the Cytokine Storm: A Conceptual Framework for Understanding, Diagnosing, and Treating Hemophagocytic Syndromes. Pediatric Clinics of North America. 2012; 59(2):329–44. https://doi.org/10.1016/j.pcl.2012.03.002 PMID: 22560573

2. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood. 2004; 104(3):735–43. https://doi.org/10.1182/blood-2003-10-3413 PMID: 15069016.

3. Prencipe G, Bracaglia C, Caiello I, Pascarella A, Francalanci P, Pardoe M, et al. The interferon-gamma pathway is selectively up-regulated in the liver of patients with secondary hemophagocytic lymphohistiocytosis. PLoS One. 2019; 14(12):e0226043. https://doi.org/10.1371/journal.pone.0226043 PMID: 31846457; PubMed Central PMCID: PMC6917341 Abbvie, Novartis, Novimmune, Roche, SOBI and received travel support from Roche and Novartis. Dr. De Benedetti is a family member of a SOBI AG employee. This does not alter our adherence to PLOS ONE policies on sharing data and materials. The other authors declare that they have no competing interests.

4. Weaver LK, Chu N, Behrens EM. Brief Report: Interferon-gamma-Mediated Immunopathology Potentiated by Toll-Like Receptor 9 Activation in a Murine Model of Macrophage Activation Syndrome. Arthritis Rheumatol. 2019; 71(1):161–8. https://doi.org/10.1002/art.40683 PMID: 30073799; PubMed Central PMCID: PMC6310087.

5. Prencipe G, Caiello I, Pascarella A, Grom AA, Bracaglia C, Chatel L, et al. Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome. J Allergy Clin Immunol. 2018; 141(4):139–49. https://doi.org/10.1016/j.jaci.2017.07.021 PMID: 28807602.

6. Brisse E, Wouters CH, Matthys P. Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2015; 26(3):263–80. https://doi.org/10.1016/j.cytogfr.2014.10.001 PMID: 25466631.

7. Vallurupalli MB N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019; 134 (21):1783–6. https://doi.org/10.1182/blood.2019002289 PMID: 31537529.

8. Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19):1811–22. https://doi.org/10.1056/NEJMoa1911326 PMID: 32374962.

9. Schmid JP, Ho CH, Chrétien F, Lefebvre JM, Pivert G, Kosco-Vilbois M, et al. Neutralization of IFNγ defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Molecular Medicine. 2009; 1(2):112–24. https://doi.org/10.1002/emmm.200900009 PMID: 20049711.

10. Wegehaupt O, Wustrau K, Lehmberg K, Ehl S. Cell Versus Cytokine—Directed Therapies for Hemophagocytic Lymphohistiocytosis (HLH) in Inborn Errors of Immunity. Front Immunol. 2020; 11:808. https://doi.org/10.3389/fimmu.2020.00808 PMID: 32457750; PubMed Central PMCID: PMC7225316.

11. Guillot A, Tacke F. Liver Macrophages: Old Dogmas and New Insights. Hepatol Commun. 2019; 3 (6):730–43. https://doi.org/10.1002/hep4.1356 PMID: 3168508; PubMed Central PMCID: PMC6545867.

12. Horras CJ, Lamb CL, Mitchell KA. Regulation of hepatocyte fate by interferon-gamma. Cytokine Growth Factor Rev. 2011; 22(1):35–43. https://doi.org/10.1016/j.cytogfr.2011.01.001 PMID: 21334249; PubMed Central PMCID: PMC3068863.

13. Lai HS, Lin WH, Hsu WM, Chen CN, Chang KJ, Lee PH. Variations in interferon gamma receptor gene expression during liver regeneration after partial hepatectomy in rats. The American surgeon. 2009; 75 (1):49–54. Epub 2009/02/14. PMID: 19213397.

14. Yin S, Wang H, Bertola A, Feng D, Xu MJ, Wang Y, et al. Activation of invariant natural killer T cells impedes liver regeneration by way of both IFN-γ- and IL-4-dependent mechanisms. Hepatology. 2014; 60(4):1356–66. Epub 2014/03/14. https://doi.org/10.1002/hep.27128 PMID: 24623351; PubMed Central PMCID: PMC4190674.
15. Sabin KF, Gantner; Gerald, Kusntle; Gisa, Tieg. Interferon Gamma Plays a Critical Role in T Cell–Dependent Liver Injury in Mice Initiated by Concanavalin A. Gastroenterology. 1996; 111:462–71. https://doi.org/10.1053/gast.1996.v111.pm8690213 PMID: 8690213

16. Arihiro Kano TH, Akaite Yoshitomo, Yoshifumi Watanabe. IRF-1 Is an Essential Mediator in IFN-gamma-Induced Cell Cycle Arrest and Apoptosis of Primary Cultured Hepatocytes. Biochemical and Biophysical Research Communications. 1999; 257:672–7. https://doi.org/10.1006/bbrc.1999.0276 PMID: 10208842

17. Buatois V, Chatel L, Cons L, Lory S, Richard F, Guilhot F, et al. Use of a mouse model to identify a blood biomarker for IFNgamma activity in pediatric secondary hepatic lymphohistiocytosis. Transl. Res. 2017; 180:37–52 e2. https://doi.org/10.1016/j.trsl.2016.07.023 PMID: 27596860; PubMed Central PMCID: PMCT7185816.

18. Rood JE, Rao S, Paessler M, Kreiager PA, Chu N, Stelekati E, et al. ST2 contributes to T-cell hyperactivation and fatal hepatic lymphohistiocytosis in mice. Blood. 2016; 127(4):426–35. https://doi.org/10.1182/blood-2015-07-659813 PMID: 26518437; PubMed Central PMCID: PMC4731846.

19. Burn TN, Weaver L, Rood JE, Chu N, Bodansky A, Kreiager PA, et al. Genetic Deficiency of Interferon-gamma Reveals Interferon-gamma-Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis. Arthritis Rheumatol. 2020; 72(2):335–47. https://doi.org/10.1002/art.41076 PMID: 31400075; PubMed Central PMCID: PMC6994338.

20. Rood JE, Burn TN, Neal V, Chu N, Behrens EM. Disruption of IL-33 Signaling Limits Early CD8+ T Cell Effector Function Leading to Exhaustion in Murine Hemophagocytic Lymphohistiocytosis. Front Immunol. 2018; 9:2642. https://doi.org/10.3389/fimmu.2018.02642 PMID: 30515155; PubMed Central PMCID: PMC6256032.

21. Biswas C, Chu N, Burn TN, Kreiager PA, Behrens EM. Amelioration of Murine Macrophage Activation Syndrome by Monomethyl Fumarate in Both a Heme Oxygenase 1-Dependent and Heme Oxygenase 1-Independent Manner. Arthritis Rheumatol. 2020. https://doi.org/10.1002/art.41591 PMID: 33191652.

22. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol. 2016; 34(5):525–7. https://doi.org/10.1038/nbt.3519 PMID: 27043002.

23. Soneson C, Love MI, Robinson MD. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res. 2015; 4:1521. https://doi.org/10.12688/f1000research.7563.2 PMID: 26928227; PubMed Central PMCID: PMC4712774.

24. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010; 26(1):139–40. https://doi.org/10.1093/bioinformatics/btp616 PMID: 19910308; PubMed Central PMCID: PMC2796818.

25. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. https://doi.org/10.1093/nar/gkv007 PMID: 25605792; PubMed Central PMCID: PMC4402510.

26. O’Connell KE, Mikkola AM, Stepaneak AM, Vernet A, Hall CD, Sun CC, et al. Practical murine hematopathology: a comparative review and implications for research. Comparative medicine. 2015; 65(2):96–113. Epub 2015/05/01. PMID: 25926395; PubMed Central PMCID: PMC4408895.

27. Meiser A, Mueller A, Wise EL, McDonagh EM, Petit SJ, Saran N, et al. The chemokine receptor CXCR3 is degraded following internalization and is replenished at the cell surface by de novo synthesis of receptor. Journal of immunology (Baltimore, Md: 1950). 2002; 169(12):7111–8. Epub 2002/12/15. PMID: 12471111.

28. Mo R, Feng XX, Wu YN, Wang H, He YP, Sun HH, et al. Hepatocytes paradoxically affect intrahepatic IFN-gamma production in autoimmune hepatitis due to Gal-9 expression and TL2R/Ligand release. Mol Immunol. 2020; 123:106–15. https://doi.org/10.1016/j.molimm.2020.05.014 PMID: 32485469.

29. Amir AZ, Ling SC, Weitzman S, Fecteau A, Grant D, et al. Liver transplantation for children with acute liver failure associated with secondary hepatic lymphohistiocytosis. Liver Transpl. 2016; 22(9):1245–53. https://doi.org/10.1002/ltr.24485 PMID: 27216884.

30. Okamoto N, Ohama H, Matsu M, Fukunishi S, Higuchi K, Asai A. Hepatic F4/80(+) CD11b(+) CD68(−) cells influence the antibacterial response in irradiated mice with sepsis due to Enterococcus faecalis. J Leukoc Biol. 2021; 109(5):943–52. https://doi.org/10.1002/jlb.4A0820-550RR PMID: 33899953.

31. Zhang Y, Shlomchik WD, Joe G, Louboutin JP, Zhu J, Rivera A, et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. Journal of immunology (Baltimore, Md: 1950). 2002; 169(12):7111–8. Epub 2002/12/10. https://doi.org/10.4049/jimmunol.169.12.7111 PMID: 12471148.
33. Chapin CA, Melin-Aldana H, Kreiger PA, Burn T, Neighbors K, Taylor SA, et al. Activated CD8 T-cell Hepatitis in Children With Indeterminate Acute Liver Failure: Results From a Multicenter Cohort. J Pediatr Gastroenterol Nutr. 2020; 71(6):713–9. https://doi.org/10.1097/MPG.0000000000002893 PMID: 32796431.

34. DiPaola F, Grimaly M, Bucuvalas J. Pediatric acute liver failure and immune dysregulation. J Pediatr. 2014; 164(2):407–9. https://doi.org/10.1016/j.jpeds.2013.10.044 PMID: 24315507.

35. Chapin CA, Taylor SA, Malladi P, Neighbors K, Melin-Aldana H, Kreiger PA, et al. Transcriptional Analysis of Liver Tissue Identifies Distinct Phenotypes of Indeterminate Pediatric Acute Liver Failure. Hepatology Communications. 2021. https://doi.org/10.1002/hep4.1726 PMID: 34430782.

36. Knolle PA, Wohlleber D. Immunological functions of liver sinusoidal endothelial cells. Cellular & molecular immunology. 2016; 13(3):347–53. Epub 04/04. https://doi.org/10.1038/cmi.2016.5 PMID: 27041636.

37. Bode SF, Ammann S, Al-Herz W, Bataneant M, Dvorak CC, Gehring S, et al. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica. 2015; 100(7):978–88. Epub 05/28. https://doi.org/10.3324/haematol.2014.121608 PMID: 26022711.

38. He Y, Hwang S, Ahmed YA, Feng D, Li N, Ribeiro M, et al. Immunopathobiology and therapeutic targets related to cytokines in liver diseases. Cell Mol Immunol. 2020. https://doi.org/10.1038/s41423-020-00580-w PMID: 33203939.

39. Chen JH, Fleming MD, Pinkus GS, Pinkus JL, Nichols KE, Mo JQ, et al. Pathology of the liver in familial hemophagocytic lymphohistiocytosis. The American journal of surgical pathology. 2010; 34(6):852–67. Epub 2010/05/06. https://doi.org/10.1097/PAS.0b013e3181dbbb17 PMID: 20426442.

40. Gloude NJ, Dandoy CE, Davies SM, Myers KC, Jordan MB, Marsh RA, et al. Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy. J Clin Immunol. 2020; 40(5):699–707. https://doi.org/10.1007/s10875-020-00789-4 PMID: 32447592; PubMed Central PMCID: PMC7245179.

41. Stipp MC, Acco A. Involvement of cytochrome P450 enzymes in inflammation and cancer: a review. Cancer Chemother Pharmacol. 2020. https://doi.org/10.1007/s00280-020-04181-2 PMID: 33112969.

42. Schuck RN, Zha W, Edin ML, Gruzdev A, Vendrov KC, Miller TM, et al. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One. 2014; 9(10):e110162. https://doi.org/10.1371/journal.pone.0110162 PMID: 26692473; PubMed Central PMCID: PMC4678374.

43. Feld JJ, Modi AA, El-Diwany R, Rotman Y, Thomas E, Ahlenstiel G, et al. S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders. Gastroenterology. 2011; 140(3):830–9. Epub 2010/09/22. https://doi.org/10.1053/j.gastro.2010.09.010 PMID: 20854821; PubMed Central PMCID: PMC3021477.

44. Lozano-Sepulveda SA, Bryan-Marrugo OL, Cordova-Fletes C, Gutierrez-Ruiz MC, Rivas-Estilla AM. Oxidative stress modulation in hepatitis C virus infected cells. World J Hepatol. 2015; 7(29):2880–9. https://doi.org/10.4254/wjh.v7.i29.2880 PMID: 26692473; PubMed Central PMCID: PMC4678374.

45. Jeong WI, Park O, Radaeva S, Gao B. STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology. 2006; 44(6):1441–51. https://doi.org/10.1002/hep.21419 PMID: 17133483.

46. Radaeva S, Sun R, Jaruga B, Nguyen VT, Tian Z, Gao B. Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners. Gastroenterology. 2006; 130(2):435–52. https://doi.org/10.1053/j.gastro.2005.10.055 PMID: 16472598.

47. He X SY, Lei N, Fan X, Zhang C, Wang Y, Zheng K, et al. MicroRNA-351 promotes schistosomiasis-induced hepatic fibrosis by targeting the vitamin D receptor. PNAS. 2018; 115:1180–5. https://doi.org/10.1073/pnas.1715965115 PMID: 29255036.

48. Weng HL, Wang BE, Jia JD, Wu WF, Xian JZ, Mertens PR, et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol. 2005; 3(8):819–28. Epub 2005/10/20. https://doi.org/10.1016/s1542-3565(05)00404-9 PMID: 16234012.

49. Weng H, Mertens PR, Gressner AM, Dooley S. IFN-gamma abrogates profibrogenic TGF-beta signaling in liver by targeting expression of inhibitory and receptor Smads. J Hepatol. 2007; 46(2):295–303. https://doi.org/10.1016/j.jhep.2006.09.014 PMID: 17125875.